Please upgrade your browser.
Kidney cancer is an often fatal disease that has touched my family. Please do not support any so-called Comparative Effectiveness scheme that could ultimately result in my loved one not receiving the therapy preferred by the patient and doctor for the treatment of cancer.
Let's hope those over 70 years of age who voted for it don't find themselves in need of an operation the government thinks is just too expensive.
It is not the responsibility of our government to determine which drugs I should be able to receive for the treatment of my kidney cancer.
Kidney Cancer Association joins the ranks of those opposed to government-run comparative effectiveness schemes that could be used to deny patients expensive medications.
The authors present the first case report of complete histologic remission after neoadjuvant sunitinib treatment on primary renal tumour and vena cava thrombus.
Autoimmune phenomena during immunotherapy are associated with favorable outcomes in patients with metastatic renal cell carcinoma.
Though comprehensive health care reform has been overshadowed by our current financial crisis, President Obama plans to make several down payments to this campaign promise in the controversial stimulus plan currently making its way through Congress.
"Comparative Effectiveness" schemes could be used by the government to restrict my right to choose the most appropriate treatment for my kidney cancer.
The molecule is in Phase II trials for treatment of metastatic renal cell carcinoma because all xenograft models responded to it.
Surgeons at the University of California, San Diego Medical Center removed a patient's diseased kidney through one incision hidden in the belly button.
|Powered by NeonCRM|